Examining the gut bacteriome, virome, and mycobiome in glucose metabolism disorders: Are we on the right track?

Metabolism: Clinical and Experimental

Volumn 73, Issue , 2017, Pages 52-66

  Stefanaki, Charikleia ^a   Peppa, Melpomeni ^b   Mastorakos, George ^c   Chrousos, George P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bacteriome; Diabetes; Microbiome; Mycobiome; Virome

Indexed keywords

GASTROINTESTINAL HORMONE;

BACTERIAL MICROBIOME; BACTEROIDES; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; GLUCOSE ABSORPTION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; LACTOBACILLUS; META ANALYSIS (TOPIC); MYCOBIOME; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGICAL PROCESS; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VIROME; VIRUS; ANIMAL; MICROFLORA; PHYSIOLOGY;

ANIMALS; GASTROINTESTINAL MICROBIOME; GLUCOSE METABOLISM DISORDERS; HUMANS; HYPERGLYCEMIA; MICROBIOTA; MYCOBIOME;

EID: 85019882011     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2017.04.014     Document Type: Review

References (111)

1. Caramia, G., Metchnikoff and the centenary of probiotics: an update of their use in gastroenteric pathology during the age of development. Minerva Pediatr 60:6 (2008), 1417–1435.
2. Metchnikoff, E., The prolongation of life. Optimistic studies. 1907, William Heinemann, London.
3. Lyte, M., The role of microbial endocrinology in infectious disease. J Endocrinol 137:3 (1993), 343–345.
4. Lyte, M., Microbial endocrinology: an ongoing personal journey. Adv Exp Med Biol 874 (2016), 1–24, 10.1007/978-3-319-20215-0_1.
5. Lyte, M., Microbial endocrinology and the microbiota-gut-brain axis. Adv Exp Med Biol 817 (2014), 3–24, 10.1007/978-1-4939-0897-4_1.
6. Lyte, M., Microbial endocrinology: host-microbiota neuroendocrine interactions influencing brain and behavior. Gut Microbes 5:3 (2014), 381–389, 10.4161/gmic.28682.
7. Docherty, N.G., le Roux, C.W., Reconfiguration of the small intestine and diabetes remitting effects of Roux-en-Y gastric bypass surgery. Curr Opin Gastroenterol 32:2 (2016), 61–66, 10.1097/MOG.0000000000000241.
8. Burcelin, R., Luche, E., Serino, M., Amar, J., The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases?. Front Biosci 14 (2009), 5107–5117.
9. Microbial ecology in states of health and disease: Workshop summary. The National Academies Collection: Reports funded by National Institutes of Health. [Washington (DC)], 2014, National Academies Press (US).
10. Ursell, L.K., Metcalf, J.L., Parfrey, L.W., Knight, R., Defining the human microbiome. Nutr Rev 70:Suppl. 1 (2012), S38–S44, 10.1111/j.1753-4887.2012.00493.x.
11. Wylie, K.M., Weinstock, G.M., Storch, G.A., Emerging view of the human virome. Transl Res 160:4 (2012), 283–290, 10.1016/j.trsl.2012.03.006.
12. Tang, J., Iliev, I.D., Brown, J., Underhill, D.M., Funari, V.A., Mycobiome: approaches to analysis of intestinal fungi. J Immunol Methods 421 (2015), 112–121, 10.1016/j.jim.2015.04.004.
13. Cui, L., Morris, A., Ghedin, E., The human mycobiome in health and disease. Genome Med, 5(7), 2013, 63, 10.1186/gm467.
14. Tilg, H., Adolph, T.E., Influence of the human intestinal microbiome on obesity and metabolic dysfunction. Curr Opin Pediatr 27:4 (2015), 496–501, 10.1097/MOP.0000000000000234.
15. Possemiers, S., Bolca, S., Verstraete, W., Heyerick, A., The intestinal microbiome: a separate organ inside the body with the metabolic potential to influence the bioactivity of botanicals. Fitoterapia 82:1 (2011), 53–66, 10.1016/j.fitote.2010.07.012.
16. Gerritsen, J., Smidt, H., Rijkers, G.T., de Vos, W.M., Intestinal microbiota in human health and disease: the impact of probiotics. Genes Nutr 6:3 (2011), 209–240, 10.1007/s12263-011-0229-7.
17. Ananthakrishnan, A.N., Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 12:4 (2015), 205–217, 10.1038/nrgastro.2015.34.
18. Diet-induced dysbiosis influences susceptibility to intestinal cancer. Cancer Discov, 4(11), 2014, 1252, 10.1158/2159–8290.CD-RW2014-192.
19. Ussher, J.R., Lopaschuk, G.D., Arduini, A., Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis 231:2 (2013), 456–461, 10.1016/j.atherosclerosis.2013.10.013.
20. Krezalek, M.A., DeFazio, J., Zaborina, O., Zaborin, A., Alverdy, J.C., The shift of an intestinal “microbiome” to a “Pathobiome” governs the course and outcome of sepsis following surgical injury. Shock, 2015, 10.1097/SHK.0000000000000534.
21. Webley, W.C., Aldridge, K.L., Infectious asthma triggers: time to revise the hygiene hypothesis?. Trends Microbiol 23:7 (2015), 389–391, 10.1016/j.tim.2015.05.006.
22. Ma, J., Prince, A.L., Bader, D., Hu, M., Ganu, R., Baquero, K., et al. High-fat maternal diet during pregnancy persistently alters the offspring microbiome in a primate model. Nat Commun, 5, 2014, 3889, 10.1038/ncomms4889.
23. Campbell, C., Grapov, D., Fiehn, O., Chandler, C.J., Burnett, D.J., Souza, E.C., et al. Improved metabolic health alters host metabolism in parallel with changes in systemic xeno-metabolites of gut origin. PLoS One, 9(1), 2014, e84260, 10.1371/journal.pone.0084260.
24. Burcelin, R., Serino, M., Chabo, C., Blasco-Baque, V., Amar, J., Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol 48:4 (2011), 257–273, 10.1007/s00592-011-0333-6.
25. American Diabetes A, Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36:4 (2013), 1033–1046, 10.2337/dc12-2625.
26. Petersen, C., Round, J.L., Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 16:7 (2014), 1024–1033, 10.1111/cmi.12308.
27. Canani, R.B., Costanzo, M.D., Leone, L., Bedogni, G., Brambilla, P., Cianfarani, S., et al. Epigenetic mechanisms elicited by nutrition in early life. Nutr Res Rev 24:2 (2011), 198–205, 10.1017/S0954422411000102.
28. Sasaki, M., Ogasawara, N., Funaki, Y., Mizuno, M., Iida, A., Goto, C., et al. Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study. BMC Gastroenterol, 13, 2013, 81, 10.1186/1471-230X-13-81.
29. Kellow, N.J., Coughlan, M.T., Savige, G.S., Reid, C.M., Effect of dietary prebiotic supplementation on advanced glycation, insulin resistance and inflammatory biomarkers in adults with pre-diabetes: a study protocol for a double-blind placebo-controlled randomised crossover clinical trial. BMC Endocr Disord, 14, 2014, 55, 10.1186/1472-6823-14-55.
30. Pories, W.J., Swanson, M.S., MacDonald, K.G., Long, S.B., Morris, P.G., Brown, B.M., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:3 (1995), 339–350 [discussion 50-2].
31. Walker, A.W., Ince, J., Duncan, S.H., Webster, L.M., Holtrop, G., Ze, X., et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J 5:2 (2011), 220–230, 10.1038/ismej.2010.118.
32. Sonnenburg, J.L., Xu, J., Leip, D.D., Chen, C.H., Westover, B.P., Weatherford, J., et al. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 307:5717 (2005), 1955–1959, 10.1126/science.1109051.
33. Thaiss, C.A., Zeevi, D., Levy, M., Zilberman-Schapira, G., Suez, J., Tengeler, A.C., et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell 159:3 (2014), 514–529, 10.1016/j.cell.2014.09.048.
34. Alkanani, A.K., Hara, N., Gottlieb, P.A., Ir, D., Robertson, C.E., Wagner, B.D., et al. Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. Diabetes 64:10 (2015), 3510–3520, 10.2337/db14-1847.
35. Achuthan, A.A., Duary, R.K., Madathil, A., Panwar, H., Kumar, H., Batish, V.K., et al. Antioxidative potential of lactobacilli isolated from the gut of Indian people. Mol Biol Rep 39:8 (2012), 7887–7897, 10.1007/s11033-012-1633-9.
36. Al-Shehri, S.S., Knox, C.L., Liley, H.G., Cowley, D.M., Wright, J.R., Henman, M.G., et al. Breastmilk-saliva interactions boost innate immunity by regulating the oral microbiome in early infancy. PLoS One, 10(9), 2015, e0135047, 10.1371/journal.pone.0135047.
37. Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley, R.E., et al. A core gut microbiome in obese and lean twins. Nature 457:7228 (2009), 480–484, 10.1038/nature07540.
38. Snider, A.J., Orr Gandy, K.A., Obeid, L.M., Sphingosine kinase: role in regulation of bioactive sphingolipid mediators in inflammation. Biochimie 92:6 (2010), 707–715, 10.1016/j.biochi.2010.02.008.
39. Kovatcheva-Datchary, P., Nilsson, A., Akrami, R., Lee, Y.S., De Vadder, F., Arora, T., et al. Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of Prevotella. Cell Metab 22:6 (2015), 971–982, 10.1016/j.cmet.2015.10.001.
40. Giongo, A., Gano, K.A., Crabb, D.B., Mukherjee, N., Novelo, L.L., Casella, G., et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J 5:1 (2011), 82–91, 10.1038/ismej.2010.92.
41. Mejia-Leon, M.E., Petrosino, J.F., Ajami, N.J., Dominguez-Bello, M.G., de la Barca, A.M., Fecal microbiota imbalance in Mexican children with type 1 diabetes. Sci Rep, 4, 2014, 3814, 10.1038/srep03814.
42. Clemente-Postigo, M., Queipo-Ortuno, M.I., Boto-Ordonez, M., Coin-Araguez, L., Roca-Rodriguez, M.M., Delgado-Lista, J., et al. Effect of acute and chronic red wine consumption on lipopolysaccharide concentrations. Am J Clin Nutr 97:5 (2013), 1053–1061, 10.3945/ajcn.112.051128.
43. Murri, M., Leiva, I., Gomez-Zumaquero, J.M., Tinahones, F.J., Cardona, F., Soriguer, F., et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med, 11, 2013, 46, 10.1186/1741-7015-11-46.
44. Vermeiren, J., Van den Abbeele, P., Laukens, D., Vigsnaes, L.K., De Vos, M., Boon, N., et al. Decreased colonization of fecal Clostridium Coccoides/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS Microbiol Ecol 79:3 (2012), 685–696, 10.1111/j.1574-6941.2011.01252.x.
45. Stewart, C.J., Nelson, A., Campbell, M.D., Walker, M., Stevenson, E.J., Shaw, J.A., et al. Gut microbiota of type 1 diabetes patients with good glycaemic control and high physical fitness is similar to people without diabetes: an observational study. Diabet Med, 2016, 10.1111/dme.13140.
46. Nurminen, N., Oikarinen, S., Hyoty, H., Virus infections as potential targets of preventive treatments for type 1 diabetes. Rev Diabet Stud 9:4 (2012), 260–271, 10.1900/RDS.2012.9.260.
47. Kramna, L., Kolarova, K., Oikarinen, S., Pursiheimo, J.P., Ilonen, J., Simell, O., et al. Gut virome sequencing in children with early islet autoimmunity. Diabetes Care 38:5 (2015), 930–933, 10.2337/dc14-2490.
48. Kolehmainen, P., Koskiniemi, M., Oikarinen, S., Veijola, R., Simell, O., Ilonen, J., et al. Human parechovirus and the risk of type 1 diabetes. J Med Virol 85:9 (2013), 1619–1623, 10.1002/jmv.23659.
49. Tapia, G., Cinek, O., Rasmussen, T., Grinde, B., Stene, L.C., Ronningen, K.S., Longitudinal study of parechovirus infection in infancy and risk of repeated positivity for multiple islet autoantibodies: the MIDIA study. Pediatr Diabetes 12:1 (2011), 58–62, 10.1111/j.1399-5448.2010.00658.x.
50. Gosiewski, T., Salamon, D., Szopa, M., Sroka, A., Malecki, M.T., Bulanda, M., Quantitative evaluation of fungi of the genus Candida in the feces of adult patients with type 1 and 2 diabetes - a pilot study. Gut Pathog, 6(1), 2014, 43, 10.1186/s13099-014-0043-z.
51. Wu, X., Ma, C., Han, L., Nawaz, M., Gao, F., Zhang, X., et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 61:1 (2010), 69–78, 10.1007/s00284-010-9582-9.
52. Benno, Y., Mitsuoka, T., Impact of Bifidobacterium longum on human fecal microflora. Microbiol Immunol 36:7 (1992), 683–694.
53. Waidmann, M., Bechtold, O., Frick, J.S., Lehr, H.A., Schubert, S., Dobrindt, U., et al. Bacteroides Vulgatus protects against Escherichia Coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology 125:1 (2003), 162–177.
54. Kabeerdoss, J., Sankaran, V., Pugazhendhi, S., Ramakrishna, B.S., Clostridium Leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India. BMC Gastroenterol, 13, 2013, 20, 10.1186/1471-230X-13-20.
55. Vidal, R., Ginard, D., Khorrami, S., Mora-Ruiz, M., Munoz, R., Hermoso, M., et al. Crohn associated microbial communities associated to colonic mucosal biopsies in patients of the western Mediterranean. Syst Appl Microbiol 38:6 (2015), 442–452, 10.1016/j.syapm.2015.06.008.
56. Larsen, N., Vogensen, F.K., van den Berg, F.W., Nielsen, D.S., Andreasen, A.S., Pedersen, B.K., et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One, 5(2), 2010, e9085, 10.1371/journal.pone.0009085.
57. Allin, K.H., Nielsen, T., Pedersen, O., Mechanisms in endocrinology: gut microbiota in patients with type 2 diabetes mellitus. Eur J Endocrinol 172:4 (2015), R167–R177, 10.1530/EJE-14-0874.
58. Chung, W.S., Walker, A.W., Louis, P., Parkhill, J., Vermeiren, J., Bosscher, D., et al. Modulation of the human gut microbiota by dietary fibres occurs at the species level. BMC Biol, 14, 2016, 3, 10.1186/s12915-015-0224-3.
59. Zeevi, D., Korem, T., Zmora, N., Israeli, D., Rothschild, D., Weinberger, A., et al. Personalized nutrition by prediction of glycemic responses. Cell 163:5 (2015), 1079–1094, 10.1016/j.cell.2015.11.001.
60. Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:7418 (2012), 55–60, 10.1038/nature11450.
61. Verdam, F.J., Greve, J.W., Roosta, S., van Eijk, H., Bouvy, N., Buurman, W.A., et al. Small intestinal alterations in severely obese hyperglycemic subjects. J Clin Endocrinol Metab 96:2 (2011), E379–E383, 10.1210/jc.2010-1333.
62. Karlsson, F.H., Tremaroli, V., Nookaew, I., Bergstrom, G., Behre, C.J., Fagerberg, B., et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498:7452 (2013), 99–103, 10.1038/nature12198.
63. Graessler, J., Qin, Y., Zhong, H., Zhang, J., Licinio, J., Wong, M.L., et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J 13:6 (2013), 514–522, 10.1038/tpj.2012.43.
64. Marambio, A., Watkins, G., Castro, F., Riffo, A., Zuniga, R., Jans, J., et al. Changes in iron transporter divalent metal transporter 1 in proximal jejunum after gastric bypass. World J Gastroenterol 20:21 (2014), 6534–6540, 10.3748/wjg.v20.i21.6534.
65. Xu, J., Lian, F., Zhao, L., Zhao, Y., Chen, X., Zhang, X., et al. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J 9:3 (2015), 552–562, 10.1038/ismej.2014.177.
66. Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermudez-Humaran, L.G., Gratadoux, J.J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105:43 (2008), 16731–16736, 10.1073/pnas.0804812105.
67. Kameyama, K., Itoh, K., Intestinal colonization by a Lachnospiraceae bacterium contributes to the development of diabetes in obese mice. Microbes Environ 29:4 (2014), 427–430, 10.1264/jsme2.ME14054.
68. Napolitano, A., Miller, S., Nicholls, A.W., Baker, D., Van Horn, S., Thomas, E., et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One, 9(7), 2014, e100778, 10.1371/journal.pone.0100778.
69. Cho, K.W., Lee, O.H., Banz, W.J., Moustaid-Moussa, N., Shay, N.F., Kim, Y.C., Daidzein and the daidzein metabolite, equol, enhance adipocyte differentiation and PPARgamma transcriptional activity. J Nutr Biochem 21:9 (2010), 841–847, 10.1016/j.jnutbio.2009.06.012.
70. Rajilic-Stojanovic, M., de Vos, W.M., The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev 38:5 (2014), 996–1047, 10.1111/1574-6976.12075.
71. De Angelis, M., Montemurno, E., Vannini, L., Cosola, C., Cavallo, N., Gozzi, G., et al. Effect of whole-grain barley on the human fecal microbiota and metabolome. Appl Environ Microbiol 81:22 (2015), 7945–7956, 10.1128/AEM.02507-15.
72. Candela, M., Biagi, E., Soverini, M., Consolandi, C., Quercia, S., Severgnini, M., et al. Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic ma-pi 2 diet. Br J Nutr, 2016, 1–14, 10.1017/S0007114516001045.
73. Porrata, C., Sanchez, J., Correa, V., Abuin, A., Hernandez-Triana, M., Dacosta-Calheiros, R.V., et al. Ma-pi 2 macrobiotic diet intervention in adults with type 2 diabetes mellitus. MEDICC Rev 11:4 (2009), 29–35.
74. Oever, J.T., Netea, M.G., The bacteriome-mycobiome interaction and antifungal host defense. Eur J Immunol 44:11 (2014), 3182–3191, 10.1002/eji.201344405.
75. Koren, O., Goodrich, J.K., Cullender, T.C., Spor, A., Laitinen, K., Backhed, H.K., et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 150:3 (2012), 470–480, 10.1016/j.cell.2012.07.008.
76. Konstantinov, S.R., van der Woude, C.J., Peppelenbosch, M.P., Do pregnancy-related changes in the microbiome stimulate innate immunity?. Trends Mol Med 19:8 (2013), 454–459, 10.1016/j.molmed.2013.06.002.
77. Angueira, A.R., Ludvik, A.E., Reddy, T.E., Wicksteed, B., Lowe, W.L. Jr., Layden, B.T., New insights into gestational glucose metabolism: lessons learned from 21st century approaches. Diabetes 64:2 (2015), 327–334, 10.2337/db14-0877.
78. Hu, J., Nomura, Y., Bashir, A., Fernandez-Hernandez, H., Itzkowitz, S., Pei, Z., et al. Diversified microbiota of meconium is affected by maternal diabetes status. PLoS One, 8(11), 2013, e78257, 10.1371/journal.pone.0078257.
79. Fugmann, M., Breier, M., Rottenkolber, M., Banning, F., Ferrari, U., Sacco, V., et al. The stool microbiota of insulin resistant women with recent gestational diabetes, a high risk group for type 2 diabetes. Sci Rep, 5, 2015, 13212, 10.1038/srep13212.
80. Gomez-Arango, L.F., Barrett, H.L., McIntyre, H.D., Callaway, L.K., Morrison, M., Nitert, M.D., et al. Connections between the gut microbiome and metabolic hormones in early pregnancy in overweight and obese women. Diabetes, 2016, 10.2337/db16-0278.
81. Nitert, M.D., Barrett, H.L., Foxcroft, K., Tremellen, A., Wilkinson, S., Lingwood, B., et al. SPRING: an RCT study of probiotics in the prevention of gestational diabetes mellitus in overweight and obese women. BMC Pregnancy Childbirth, 13, 2013, 50, 10.1186/1471-2393-13-50.
82. Laitinen, K., Poussa, T., Isolauri, E., Nutrition AMI, Intestinal Microbiota G, Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. Br J Nutr 101:11 (2009), 1679–1687, 10.1017/S0007114508111461.
83. Egshatyan, L., Kashtanova, D., Popenko, A., Tkacheva, O., Tyakht, A., Alexeev, D., et al. Gut microbiota and diet in patients with different glucose tolerance. Endocr Connect 5:1 (2016), 1–9, 10.1530/EC-15-0094.
84. Martinez, I., Lattimer, J.M., Hubach, K.L., Case, J.A., Yang, J., Weber, C.G., et al. Gut microbiome composition is linked to whole grain-induced immunological improvements. ISME J 7:2 (2013), 269–280, 10.1038/ismej.2012.104.
85. Cani, P.D., Everard, A., Akkermansia muciniphila: a novel target controlling obesity, type 2 diabetes and inflammation?. Med Sci (Paris) 30:2 (2014), 125–127, 10.1051/medsci/20143002003.
86. Everard, A., Cani, P.D., Gut microbiota and GLP-1. Rev Endocr Metab Disord 15:3 (2014), 189–196, 10.1007/s11154-014-9288-6.
87. Lambeth, S.M., Carson, T., Lowe, J., Ramaraj, T., Leff, J.W., Luo, L., et al. Composition, diversity and abundance of gut microbiome in prediabetes and type 2 diabetes. Journal of diabetes and obesity 2:3 (2015), 1–7, 10.15436/2376–0949.15.031.
88. Gao, B., Gupta, R.S., Phylogenetic framework and molecular signatures for the main clades of the phylum Actinobacteria. Microbiol Mol Biol Rev 76:1 (2012), 66–112, 10.1128/MMBR.05011-11.
89. Trejo, A.G., Chittenden, G.J., Buchanan, J.G., Baddiley, J., Uridine diphosphate alpha-D-galactofuranose, an intermediate in the biosynthesis of galactofuranosyl residues. Biochem J 117:3 (1970), 637–639.
90. Suzuki, Y.A., Shin, K., Lonnerdal, B., Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 40:51 (2001), 15771–15779.
91. Duncan, S.H., Louis, P., Flint, H.J., Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl Environ Microbiol 70:10 (2004), 5810–5817, 10.1128/AEM.70.10.5810-5817.2004.
92. Salter, S.J., Cox, M.J., Turek, E.M., Calus, S.T., Cookson, W.O., Moffatt, M.F., et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol, 12, 2014, 87, 10.1186/s12915-014-0087-z.
93. Zhang, X., Shen, D., Fang, Z., Jie, Z., Qiu, X., Zhang, C., et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One, 8(8), 2013, e71108, 10.1371/journal.pone.0071108.
94. Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J.P., Druart, C., Bindels, L.B., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110:22 (2013), 9066–9071, 10.1073/pnas.1219451110.
95. Qiu, X., Zhang, M., Yang, X., Hong, N., Yu, C., Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J Crohns Colitis 7:11 (2013), e558–e568, 10.1016/j.crohns.2013.04.002.
96. Karlsson, F.H., Fak, F., Nookaew, I., Tremaroli, V., Fagerberg, B., Petranovic, D., et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun, 3, 2012, 1245, 10.1038/ncomms2266.
97. Saulnier, D.M., Riehle, K., Mistretta, T.A., Diaz, M.A., Mandal, D., Raza, S., et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141:5 (2011), 1782–1791, 10.1053/j.gastro.2011.06.072.
98. Stefanaki, C., Roma-Giannikou, E., Mantzou, E., Paltoglou, G., Landis, D., Bacopoulou, F., Adolescents with prediabetes lack key species by quantitative, core gut microbiome analysis - a case-control study. Society TE, (eds.) Endocrine Society's 98th annual meeting and expo; April 3, 2016; Boston, Massachusetts, 2016.
99. Ciubotaru, I., Green, S.J., Kukreja, S., Barengolts, E., Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans. Transl Res 166:5 (2015), 401–411, 10.1016/j.trsl.2015.06.015.
100. Bashir, M., Prietl, B., Tauschmann, M., Mautner, S.I., Kump, P.K., Treiber, G., et al. Effects of high doses of vitamin D3 on mucosa-associated gut microbiome vary between regions of the human gastrointestinal tract. Eur J Nutr 55:4 (2016), 1479–1489, 10.1007/s00394-015-0966-2.
101. Semenkovich, C.F., Danska, J., Darsow, T., Dunne, J.L., Huttenhower, C., Insel, R.A., et al. American Diabetes Association and JDRF research symposium: diabetes and the microbiome. Diabetes 64:12 (2015), 3967–3977, 10.2337/db15-0597.
102. De Paepe, M., Leclerc, M., Tinsley, C.R., Petit, M.A., Bacteriophages: an underestimated role in human and animal health?. Front Cell Infect Microbiol, 4, 2014, 39, 10.3389/fcimb.2014.00039.
103. Minot, S., Bryson, A., Chehoud, C., Wu, G.D., Lewis, J.D., Bushman, F.D., Rapid evolution of the human gut virome. Proc Natl Acad Sci U S A 110:30 (2013), 12450–12455, 10.1073/pnas.1300833110.
104. Abedon, S.T., Ecology of anti-biofilm agents I: antibiotics versus bacteriophages. Pharmaceuticals 8:3 (2015), 525–558, 10.3390/ph8030525.
105. Saxena, A., Sitaraman, R., Osmoregulation and the human mycobiome. Front Microbiol, 5, 2014, 167, 10.3389/fmicb.2014.00167.
106. Brown, C.T., Davis-Richardson, A.G., Giongo, A., Gano, K.A., Crabb, D.B., Mukherjee, N., et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One, 6(10), 2011, e25792, 10.1371/journal.pone.0025792.
107. Lyte, M., The effect of stress on microbial growth. Anim Health Res Rev 15:2 (2014), 172–174, 10.1017/S146625231400019X.
108. Aagaard, K., Petrosino, J., Keitel, W., Watson, M., Katancik, J., Garcia, N., et al. The human microbiome project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J 27:3 (2013), 1012–1022, 10.1096/fj.12-220806.
109. Feng, R., Shou, J.W., Zhao, Z.X., He, C.Y., Ma, C., Huang, M., et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep, 5, 2015, 12155, 10.1038/srep12155.
110. Wang, Yan, J-WS, Xiao-Yang, Zhao, Zhen-Xiong, Fu, Jie, He, Chi-Yu, et al. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism 70:May 2017 (2017), 72–84 http://doi.org/10.1016/j.metabol.2017.02.003.
111. Freestone, P.P., Lyte, M., Neal, C.P., Maggs, A.F., Haigh, R.D., Williams, P.H., The mammalian neuroendocrine hormone norepinephrine supplies iron for bacterial growth in the presence of transferrin or lactoferrin. J Bacteriol 182:21 (2000), 6091–6098.